Latest news with #geneticdiseases
Yahoo
4 days ago
- Business
- Yahoo
Truist Sees Upside in BridgeBio Pharma's (BBIO) ATTR-CM Strategy
BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 21, Truist Securities initiated coverage of BBIO with a Buy rating and a $66 price target, spotlighting the promising launch of Attruby for treating ATTR-CM. A closeup of a medical technician handling a sample of a biopharmaceutical drug. Citing its growing use as a first-line therapy due to ease of access and better stabilizer data, Truist sees strong traction among tafamidis-progressing patients. With the ATTR-CM market expected to reach $20 billion, Truist views significant upside for Attruby despite ongoing patent litigation from Pfizer. The firm remains optimistic about BridgeBio's IP position and also highlighted near-term growth catalysts from its late-stage pipeline, particularly starting in the second half of 2025. BridgeBio Pharma Inc. (NASDAQ:BBIO) is a biopharmaceutical company that develops and delivers transformative medicines for genetic diseases and cancers with clear genetic drivers. It boasts a pipeline of candidate drugs, some in early-stage research and others in advanced clinical trials. While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Globe and Mail
22-07-2025
- Business
- Globe and Mail
BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET
PALO ALTO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ('BridgeBio' or the 'Company'), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its second quarter financial results and business updates after the market closes on Tuesday, August 5, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio's presentation, please visit the 'Events & Presentations' page within the Investors section of the BridgeBio website at A replay of the webcast will be available on the BridgeBio website for 30 days following the event. Participants may access the webcast by registering online using the following link, About BridgeBio Pharma, Inc. BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit and follow us on LinkedIn, Twitter, Facebook, and YouTube.
Yahoo
21-07-2025
- Business
- Yahoo
Sharp Therapeutics Corp. Announces Results from Annual Meeting of Shareholders
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 21, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical biotechnology company developing small molecule therapies to treat genetic diseases, is pleased to announce the voting results from its annual general meeting of shareholders held on July 18, 2024 (the "Meeting"). All nominees set forth in the Company's management information circular dated June 10, 2025 (the "Circular") were elected as directors of the Company at the Meeting. Detailed results of the votes are set out below: Nominee Number of Shares Percentage of Votes For Withheld For Withheld Scott Sneddon 10,923,102 0 100 % 0% William R. Newlin 10,923,102 0 100 % 0% John L. Brooks III 10,923,102 0 100 % 0% Dietrich Stephan 10,923,102 0 100 % 0% John Hathaway 10,923,102 0 100 % 0% Lorne Sugarman 10,923,102 0 100 % 0% The Circular also sought approval to re-appoint MNP LLP as auditors of the Company and to authorize the board of directors of the Company to fix the auditors' remuneration. The results of the shareholder votes for this item is set out below: Motion Number of Shares For Percentage of Votes For Appointment of Auditors 10,923,102 100 % About Sharp Therapeutics Corp. First-Choice Therapies for Genetic Diseases Sharp Therapeutics is a pre-clinical stage company developing first-choice small-molecule therapeutics for genetic diseases. The Company's discovery platform combines novel high throughput screening technologies, with compound libraries computational optimized based on the physics and biology of cellular trafficking defects and allosteric activation of proteins. The platform produces small molecule compounds that restore activity in mutated proteins giving the potential to treat genetic disorders with conventional pill-based medicines. For additional information on Sharp, please visit: Contacts:Scott Sneddon, PhD, JDChief Executive Officer412-206-5303 or scott@ Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. To view the source version of this press release, please visit
Globe and Mail
21-07-2025
- Business
- Globe and Mail
Sharp Therapeutics Corp. Announces Results from Annual Meeting of Shareholders
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 21, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (" Sharp" or the " Company"), a pre-clinical biotechnology company developing small molecule therapies to treat genetic diseases, is pleased to announce the voting results from its annual general meeting of shareholders held on July 18, 2024 (the " Meeting"). All nominees set forth in the Company's management information circular dated June 10, 2025 (the " Circular") were elected as directors of the Company at the Meeting. Detailed results of the votes are set out below: The Circular also sought approval to re-appoint MNP LLP as auditors of the Company and to authorize the board of directors of the Company to fix the auditors' remuneration. The results of the shareholder votes for this item is set out below: Motion Number of Shares For Percentage of Votes For Appointment of Auditors 10,923,102 100 % About Sharp Therapeutics Corp. First-Choice Therapies for Genetic Diseases Sharp Therapeutics is a pre-clinical stage company developing first-choice small-molecule therapeutics for genetic diseases. The Company's discovery platform combines novel high throughput screening technologies, with compound libraries computational optimized based on the physics and biology of cellular trafficking defects and allosteric activation of proteins. The platform produces small molecule compounds that restore activity in mutated proteins giving the potential to treat genetic disorders with conventional pill-based medicines. For additional information on Sharp, please visit: To view the source version of this press release, please visit
Reuters
18-07-2025
- Health
- Reuters
Three-person IVF technique prevents inherited diseases, scientists say
Eight children in the UK have been spared from devastating genetic diseases thanks to a new three-person in vitro fertilization technique that transfers pieces from inside the mother's fertilized egg into a healthy egg provided by an anonymous donor, scientists from Newcastle University reported on Wednesday (July 16). Kristy Kilburn reports.
